# Part 3B – Additional Data Requirements and Future Schema Evolution

The success metric used in this analysis is an **Operational Completion Rate (OCR)**, where completed trials are treated as successes and terminated/withdrawn trials as failures. While this provides a reproducible way to evaluate trial progression, it is important to recognize that trial completion is not equivalent to therapeutic success.

A completed trial may fail its primary endpoint, while a terminated trial may stop for reasons unrelated to efficacy. Therefore, OCR should be interpreted as an operational development metric rather than a clinical outcome metric.

To better define success, I would want access to additional trial-level and outcome-level data, including:

* Primary and secondary endpoint results
* Objective response rate (ORR)
* Progression-free survival (PFS)
* Overall survival (OS)
* Adverse event and safety data
* Regulatory outcomes (approval, rejection, accelerated approval, etc.)
* Trial arm-level results rather than trial-level summaries

With these data, success could be redefined using clinically meaningful endpoints rather than completion status alone. For example, a trial could be considered successful if it met its primary endpoint, demonstrated statistically significant improvement over the control arm, or ultimately contributed to a regulatory approval.

The current schema was designed around the information available in the source dataset. The normalized structure separates trials, indications, drugs, and molecular targets into dedicated bridge tables, allowing flexible cohort-level analysis.

If richer clinical data became available, I would extend the schema by introducing additional entities such as:

* Trial arms
* Endpoint results
* Safety outcomes
* Biomarker information
* Regulatory decisions
* Sponsor and investigator metadata

This would allow analyses at multiple levels, such as:

* Success rates by biomarker-defined population
* Target-specific efficacy trends
* Technology-specific safety profiles
* Phase transition probabilities
* Approval likelihood by indication or target class

One interesting observation from this dataset was that completion rates varied across phases, indications, targets, and technology classes. However, because the analysis is based on operational outcomes, these findings should be interpreted as differences in trial progression rather than differences in therapeutic effectiveness.

Overall, the pipeline developed here provides a reproducible framework for transforming raw oncology trial data into an analytical dataset. With access to endpoint and regulatory data, the same framework could be extended to evaluate true clinical and developmental success rather than operational completion alone.
